ABT : Analysis & Opinions

  1. The 8 Top Business Incubators

    September 28, 2015
    Business incubators can play a crucial role in the life of a start-up. Here's our list of the top eight incubators
  2. Worried About a Recession? Then Buy These 5 Stocks

    April 10, 2015
    What makes these stocks so resilient? And how did they perform during the last crisis?
  3. How is a Spinoff Worth $100 Billion? See AbbVie

    April 1, 2015
    An in depth look at Abbott Labs spinoff AbbVie and how it became a nearly $100 billion company.
  4. The Future of Big Pharma Stocks

    March 31, 2015
    A look at the future health of big pharma stocks.
  5. Interested In Pharmaceutical Stocks? Try Novartis (ADR)

    February 26, 2015
    Novartis AG, is the world's leading pharmaceutical company by sales. Here is a closer look at Novartis, and how its financials ...
  6. Your Best Bet for Healthcare Stocks: The XHE ETF

    January 20, 2015
    With the decent growth and wide profit margins of medical device companies, the XHE ETF shouldn't be ignored.
  7. 5 Family-Friendly Employers For Working Parents

    July 31, 2014
    A family friendly employer doesn’t just make it possible for parents who work there to care for their children without ...
  8. Stocks Turning Higher After a Pullback

    April 30, 2014
    Four stocks with a recent pullback during a stong overall uptrend, and may be setting to pop higher again.
  9. There’s Still Room For Dividends In Your Portfolio

    January 7, 2014
    When the Fed decided to begin tapering, it sent shockwaves throughout the dividend stock sector. However, those “shockwaves” ...
  10. The Street Has Caught Covidien

    August 1, 2013
    Covidien's quality isn't the issue, but Wall Street's love for it may be.
  11. Roche Delivering Leverage, But Still Needs Diversification

    July 29, 2013
    If Roche can balance out its sales mix, the long-term value could be quite compelling at present prices.
  12. Abbott Labs Making Progress On Margins, Now It Needs More Growth

    July 17, 2013
    Abbott's results were just so-so, as both margins and growth need more momentum.
  13. Abbott Adds Two Promising Products

    July 15, 2013
    Abbott makes two solid growth acquisitions that should address large markets.
  14. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  15. It Gets A Little Harder From Here For Covidien

    April 29, 2013
    Expectations are the bigger issue for Covidien, as underlying growth is still pretty good on a relative basis.
  16. Strategy for Trading High Flying Healthcare Stocks

    April 17, 2013
    Over the past week, month and three months, the healthcare sector has been the top performer.
  17. Pharma Is Doing All The Pulling For Johnson & Johnson

    April 17, 2013
    Although JNJ reported decent earnings and has some major new drugs lined up - downside risk is definitely still present.
  18. The Cyprus Crisis 101

    March 19, 2013
    Discover what's behind the Cyprus debacle and what investors should do about the situation.
  19. Mead Johnson Nutrition's Valuation Looks Bloated

    February 5, 2013
    Mead Johnson seems overvalued for its above-average growth prospects.
  20. Shabby Reporting And Questionable Prospects At Abbott Labs

    January 28, 2013
    Poor reporting and weak margins undermine the potential of Abbott.
  21. Abbott Labs Spins Off AbbVie: Which Is The Better Buy?

    January 4, 2013
    January 2 was the first day of trading for the pharmaceutical spin-off.
  22. BASF's Deal For Pronova Shows The Importance Of Good Nutrition

    November 23, 2012
    BASF ties up another high-grade fish oil company in Pronovna, adding to the recent rise in popularity for the fish oil space.
  23. Drugs Have Moved J&J On To A New Phase

    October 17, 2012
    J&J is back on a growth track, but the device business needs fixing.
  24. Abbott Laboratories Third Quarter Earnings Preview

    October 12, 2012
    On Wednesday, October 17, 2012, Abbott Laboratories (NYSE:ABT) is expected to release its third quarter earnings. Investors ...
  25. Agilent Seeing Tougher Conditions, But Still A Quality Pick

    August 17, 2012
    Agilent's end markets have weakened, but the company looks well-positioned for the long term.
  26. More Healthy Alternatives To Zimmer

    July 30, 2012
    Zimmer has turned to cost cutting to keep total profit growth moving positively forward, but doesn't appear to have any answers ...
  27. Healthcare Stocks Continuing To Outperform

    July 18, 2012
    These healthcare stocks are still on fire, with potentially more upside left. But is that actually bad for the stock market?
  28. Bio-Reference Labs Taking Advantage Of Esoteric Opportunities

    June 22, 2012
    The decision of whether to buy Bio-Reference really comes down to an investor's confidence in the growth prospects for the ...
  29. ilent Pays A Hefty Price For A Fixer-Upper Diagnostics Company

    May 22, 2012
    Agilent is paying up to get into the increasingly crowded diagnostics market.
  30. 6 Stocks With Dividends And Growth

    April 30, 2012
    Growth and dividends don't have to be an either/or choice.
  31. Nestle Almost Never On Sale

    April 24, 2012
    Nestle has a well-earned reputation for excellence and the Street has long been happy to pay a premium for that performance. ...
  32. 6 Overbought Stocks To Watch

    March 30, 2012
    Let's take a look at a few stocks that have recently entered overbought territory because these could be candidates for a ...
  33. Smart Stocks To Rally With

    March 28, 2012
    As the market advances, investing risk naturally increases but seeking out quality companies where you can pay below a reasonable ...
  34. Rallying Large Caps With Strong Sources Of Profitability

    March 12, 2012
    The market rallied to make up for last week's drop.
  35. Weight Watchers – Yo-Yo Performance And Debt Gluttony

    February 16, 2012
    Weight Watchers is increasing its already prodigious debt load for no good purpose.
  36. The 10 Must-Know Market Forces for 2012

    February 14, 2012
    For the first time since 2007, investors have multiple ways to succeed this year. Understanding how the lingering effects ...
  37. 2 of the Safest Stock Bets Around

    February 14, 2012
    Picking stocks that are increasing dividend payouts and growing in price, while meeting the moral requirements of a Catholic ...
  38. Abbott Labs Dividing Its Growth And Income Potential

    January 26, 2012
    With the coming split of operations, Abbott Labs investors will better be able to choose between growth and income.
  39. Stryker Leaning Away From Knees

    January 26, 2012
    A fair amount of future growth is already baked into Stryker’s valuation.
  40. 4 Stocks To Contemplate Before Wednesday

    January 24, 2012
    Here are four companies that will be releasing their earnings on January 25th.
  41. 2011 - Another Sick Year For Larger Med-Tech

    December 29, 2011
    Larger healthcare companies are still getting sickly returns in the market.
  42. Healthcare Stocks On The Move

    December 13, 2011
    These four healthcare stocks are showing above-average performance.
  43. 3 Price-to-Book Gems

    November 30, 2011
    Quality companies with low price to book value ratios have outperformed companies with higher valuations for the past three-, ...
  44. Will Qiagen's Restructuring Address The Real Problems?

    November 30, 2011
    Will Qiagen's Restructuring Address The Real Problems?
  45. Covidien Delivers Once Again

    November 21, 2011
    Covidien is overlooked and undervalued.
  46. Meridian Biosciences – Stealth Income Play

    November 16, 2011
    Meridian offers an impressive dividend, but a high valuation as well.
  47. Is Hologic A Coiled Spring?

    November 11, 2011
    Hologic looks cheap on even modest growth recovery expectations.
  48. Abbott Labs Joins The Separation Movement

    October 24, 2011
    Abbott is joining the separation movement that is sweeping across corporate America. The company plans to break into a medical ...
  49. Protect On The Downside With J&J

    October 21, 2011
    J&J trades at a reasonable forward P/E and offers investors downside protection.
  50. XOMA Rearranges The Deck Chairs One More Time

    September 2, 2011
    XOMA changes management again, but should anybody care?
  51. 5 Bullish Macd Crossovers

    August 17, 2011
    Knowing when trends are about to reverse is tricky business, but the MACD can help.
  52. BD Healthy, But No Great Bargain

    August 9, 2011
    BD is not the cheapest health care name, but it comes with a lot of quality.
  53. 6 Dividend Stocks Paying High Yields

    August 7, 2011
    John Buckingham of The Prudent Speculator likes undervalued large caps with dividend yields better than the ten-year Treasury. ...
  54. The Perpetual Boston Scientific Turnaround Story

    August 4, 2011
    Another quarter brings another hope for better days at BSX.
  55. Top Drug Stocks

    June 30, 2011
    Recently, three strong factors are driving investors to the drug sector.
  56. Pleasure And Pain For Pfizer

    June 27, 2011
    Pfizer sees a new pain pill make it to market and another sent back to the drawing board.
  57. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  58. Johnson & Johnson Surrenders In Stents

    June 17, 2011
    JNJ makes a tough and surprising, but ultimately wise, decision.
  59. Should Investors Worry If Gen-Probe Doesn't Sell Out?

    June 10, 2011
    Not selling may be the best move Gen-Probe can make for its shareholders.
  60. Medtronic Still Muddling Through

    May 27, 2011
    Medtronic is going nowhere fast, but the quality hasn't left.
  61. Will Nestle Succeed Where Others Have Failed?

    May 26, 2011
    Nestle is making an interesting step into medical pharmaceuticals and diagnostics.
  62. 4 Defensive Stocks To Defend Against A Downturn

    May 25, 2011
    Large, defensive stocks pose minimal risk for the upside potential.
  63. Hologic Holding The Line

    May 4, 2011
    Hologic lacks exciting growth, but the technology is in place for better growth in the future.
  64. Teva And Cephalon Solve Each Other's Problems

    May 4, 2011
    Teva's acquisition of Cephalon is a logical deal that solves problems for each company.
  65. Despite The Noise, Abbott Still A Value

    April 25, 2011
    Abbott has made some curious moves of late, but the value is still there.
  66. Can St. Jude Live Up To Newfound Expectations?

    April 25, 2011
    St. Jude faces something it has rarely seen in the past - high expectations.
  67. 5 Low Risk Stocks On The S&P

    April 12, 2011
    Check out five low-beta stocks that can help you to diversify your portfolio.
  68. The Market's Most Overestimated Stocks

    April 1, 2011
    The market loves a good story stock, but sometimes, the math behind the story doesn't paint a very pretty picture.
  69. Quest Diagnostics Opens Its Wallet One More Time

    March 22, 2011
    Quest shows once again that it is willing to pay for what may become valuable testing technology.
  70. DexCom Shows Diabetes Still A Growth Industry

    March 9, 2011
    DexCom shows that, although times are tough, people will still adopt better technology.
  71. Medtronic's Midlife Crisis

    February 24, 2011
    Medtronic lacks growth, but quality is still in place.
  72. Danaher Hopes To Revive Beckman Coulter

    February 9, 2011
    Learn more about Danaher's expensive, albeit strategic, bid for a leading diagnostics franchise.
  73. A Royal Present For Martek Shareholders

    December 23, 2010
    DSM furthers its transition to a food and health-focused chemical company.
  74. Big Dividends In Large Caps

    December 17, 2010
    These five stocks pay good dividends and can help balance an otherwise unstable portfolio.
  75. FDA's Bizarro World - Orexigen Gets Panel Approval!

    December 8, 2010
    In a surprise decision, an FDA panel votes to approve Contrave, Orexigen's new obesity drug.
  76. 6 Stocks Poised To Pop

    November 30, 2010
    Let's take a look at a few stocks that have recently entered oversold territory because these could be candidates for a short-term ...
  77. Abbott Labs Showing Meaningful Growth

    October 21, 2010
    Abbott might just be the best healthcare stock today.
  78. 4 Companies That Should Have Sold Out

    September 9, 2010
    When company management gets unreasonably stubborn and refuses a merger or buyout, shareholders often pay the price.
  79. Biotech Stocks Ready Ready To Break Out

    September 7, 2010
    Biotech Stocks Ready Ready To Break Out
  80. Revealing Four Companies' Earnings Quality

    August 17, 2010
    How to perform a quick quality test to ascertain a company's earnings quality.
  81. Novartis On The Right Track

    July 19, 2010
    With recent sales increases and a solid pipeline, Novartis deserves a spot on the watchlist of anybody looking at Big Pharma.
  82. Stocks To Guard Your Portfolio

    July 1, 2010
    Finding the right stock to reduce volatility is not as exciting, but it is essential to building a lasting portfolio and ...
  83. Can Investors Fatten Up On Weight Loss?

    June 22, 2010
    Obesity is described as a multi-billion dollar crisis in North America, but how can investors profit from the solutions?
  84. Great Dividend Payers In Medical Technology

    May 21, 2010
    Dividend-paying stocks are not common in medical technology, but these four proven winners deliver the goods.
  85. Becton Dickinson More Interesting Than You Think

    May 3, 2010
    Becton Dickinson is often dismissed as "boring" but a diversified cash-generating business with real growth shouldn't be.
  86. Pharmaceutical Profits That Aren't For The Dogs

    March 15, 2010
    Merck and Sanofi-Aventis recently combined their animal health businesses, lending further evidence to the notion that this ...
  87. Time To Shift To Quality

    September 30, 2009
    These big-cap quality names appear value priced. But is this the right time to buy in?
  88. Medical Devices: Cure For Ailing Portfolios?

    February 27, 2009
    Find out how these medical device makers may resuscitate your ailing portfolio.
  89. Invest In The Original S&P 500

    February 18, 2009
    An amazing number of the original companies in the S&P 500 index are still trading. I'll pick out some interesting choices ...
  90. Abbott Labs Shows Textbook Case For Turnaround

    October 9, 2008
    ABT is nearing a long-term support level, which could prop up the price of the shares.
  91. What Imclone Means To Eli Lilly

    October 7, 2008
    Eli Lilly expands its cancer offering with the acquisition of Imclone. Can the union boost Eli Lilly's floundering stock ...
  92. Who's Really Winning The Heart-Stent Race?

    May 14, 2008
    All the stent makers claim they're the sole industry leader. We help cut through the clutter.
  93. Abbott Labs Finally Turns Potential Into Profit

    April 17, 2008
    Solid numbers for the last two quarters could change Abbott Labs's reputation as an overvalued stock.
  94. Abbott Labs Healing Nicely (ABT)

    April 17, 2007
    ABT's Q4 earnings were a pleasant surprise. It's poised to surprise investors again when it releases earnings later this ...
  95. Bristol-Myers Hurt By Plavix, Saved By Demographics (BMY)

    November 16, 2006
    Despite BMY's recent struggles with its Plavix sales, favorable demographics make the stock a good investment to consider.
  96. Boston Scientific Shaken, But Not Stirred (BSX)

    November 8, 2006
    Boston Scientific looks poised for higher per share valuations in the future.
Trading Center